What is the difference between Dulaglutide and Efpeglenatide?

Dulaglutide is classified as: Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 analogue fused to a modified human IgG4 Fc fragment). Efpeglenatide is classified as: Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (exendin-based, once-weekly). Dulaglutide is approved for one or more medical uses in at least one major jurisdiction. Efpeglenatide is investigational and is not an approved medicine.

Is Dulaglutide or Efpeglenatide approved?

Dulaglutide is approved for one or more medical uses in at least one major jurisdiction. Efpeglenatide is investigational and is not an approved medicine. Regulatory status by region is set out in the table above.

How much clinical trial evidence is tracked for Dulaglutide and Efpeglenatide?

Peptide Science Daily tracks 138 registered clinical trials for Dulaglutide (evidence grade A) and 5 for Efpeglenatide (evidence grade B).

Compound comparison

Dulaglutide vs Efpeglenatide

This page sets Dulaglutide and Efpeglenatide side by side using the data recorded on Peptide Science Daily: drug class, mechanism of action, regulatory status by region, the evidence grade assigned here, and the number of clinical trials tracked. It is a neutral, factual comparison and does not rank either compound or recommend one over the other.

Side-by-side comparison

Class: Dulaglutide
Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 analogue fused to a modified human IgG4 Fc fragment)
Efpeglenatide
Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (exendin-based, once-weekly)
Mechanism: Dulaglutide
In plain terms, dulaglutide copies a natural gut hormone that lowers blood sugar and curbs appetite.
Efpeglenatide
In plain terms, efpeglenatide mimics the gut hormone GLP-1, prompting the pancreas to release insulin when blood sugar is high, curbing appetite, and slowing stomach emptying.
United States (FDA): Dulaglutide
Approved. Trulicity for type 2 diabetes (2014); an indication to reduce major adverse cardiovascular events in adults with type 2 diabetes was added in 2020.
Efpeglenatide
Not approved. Efpeglenatide remains an investigational agent with no FDA marketing authorization.
European Union (EMA): Dulaglutide
Authorized (Trulicity) for type 2 diabetes (marketing authorization granted 2014).
Efpeglenatide
Not authorised. No EMA marketing authorization.
Australia (TGA): Dulaglutide
Registered on the ARTG (Trulicity) for type 2 diabetes, available on prescription.
Efpeglenatide
Not registered on the ARTG. Investigational only.
WADA: Dulaglutide
Not prohibited. GLP-1 receptor agonists are not on the WADA Prohibited List and are not banned substances.
Efpeglenatide
Not listed as a prohibited substance on the WADA Prohibited List (2026). GLP-1 receptor agonists are not classified as prohibited in or out of competition.
Evidence grade: Dulaglutide
A
Efpeglenatide
B
Tracked clinical trials: Dulaglutide
138
Efpeglenatide
5
Full profile: Dulaglutide
Dulaglutide profile
Efpeglenatide
Efpeglenatide profile

Comparison of Dulaglutide and Efpeglenatide by class, mechanism, regulatory status by region, evidence grade, and number of tracked clinical trials.
Attribute	Dulaglutide	Efpeglenatide
Class	Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 analogue fused to a modified human IgG4 Fc fragment)	Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (exendin-based, once-weekly)
Mechanism	In plain terms, dulaglutide copies a natural gut hormone that lowers blood sugar and curbs appetite.	In plain terms, efpeglenatide mimics the gut hormone GLP-1, prompting the pancreas to release insulin when blood sugar is high, curbing appetite, and slowing stomach emptying.
United States (FDA)	Approved. Trulicity for type 2 diabetes (2014); an indication to reduce major adverse cardiovascular events in adults with type 2 diabetes was added in 2020.	Not approved. Efpeglenatide remains an investigational agent with no FDA marketing authorization.
European Union (EMA)	Authorized (Trulicity) for type 2 diabetes (marketing authorization granted 2014).	Not authorised. No EMA marketing authorization.
Australia (TGA)	Registered on the ARTG (Trulicity) for type 2 diabetes, available on prescription.	Not registered on the ARTG. Investigational only.
WADA	Not prohibited. GLP-1 receptor agonists are not on the WADA Prohibited List and are not banned substances.	Not listed as a prohibited substance on the WADA Prohibited List (2026). GLP-1 receptor agonists are not classified as prohibited in or out of competition.
Evidence grade	A	B
Tracked clinical trials	138	5
Full profile	Dulaglutide profile	Efpeglenatide profile

Common questions

What is the difference between Dulaglutide and Efpeglenatide?: Dulaglutide is classified as: Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (GLP-1 analogue fused to a modified human IgG4 Fc fragment). Efpeglenatide is classified as: Long-acting glucagon-like peptide-1 (GLP-1) receptor agonist (exendin-based, once-weekly). Dulaglutide is approved for one or more medical uses in at least one major jurisdiction. Efpeglenatide is investigational and is not an approved medicine.
Is Dulaglutide or Efpeglenatide approved?: Dulaglutide is approved for one or more medical uses in at least one major jurisdiction. Efpeglenatide is investigational and is not an approved medicine. Regulatory status by region is set out in the table above.
How much clinical trial evidence is tracked for Dulaglutide and Efpeglenatide?: Peptide Science Daily tracks 138 registered clinical trials for Dulaglutide (evidence grade A) and 5 for Efpeglenatide (evidence grade B).